Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.47 |
| ▸ | PPARD | Q03181 | 8/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952620 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL27649492 | 0.84 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL27649491 | 0.84 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3957552 | 0.84 | PPARD (0.43) | PPARDFFAR1PPARA | |
| SCHEMBL4506871 | 0.84 | PPARD (0.43) | PPARDFFAR1PPARA | |
| SCHEMBL3020498 | 0.83 | ESR1 (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3953256 | 0.82 | PPARD (0.42) | PPARDFFAR1PPARA | |
| SCHEMBL4496981 | 0.82 | PPARD (0.42) | PPARDFFAR1PPARA | |
| SCHEMBL4497378 | 0.81 | PPARD (0.51) | PPARDFFAR1PPARA | |
| SCHEMBL3957347 | 0.81 | PPARD (0.51) | PPARDFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605171-B2 | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080249093-A1 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists | MERCK & CO., INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249093-A1 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists | S1PR1, S1PR3, S1PR5 | ADRA2A 376/4885ADRA2B 410/4885ADRA2C 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.